(株)レナサイエンス
株価チャート
2026/07/21 更新株価トレンド
2026/07/21 更新株価・取引詳細
2026/07/21 更新株価
取引
株主構成
2026/07/01 更新財務パフォーマンス
2026/07/19 更新売上・利益
利益率
キャッシュフロー
財務健全性
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| 損益計算書 | ||||
| 売上高 | ¥1億 | ¥2億 | ¥1億 | ¥1億 |
| 売上総利益 | ¥1億 | ¥2億 | ¥1億 | ¥1億 |
| 営業利益 | -¥3億 | -¥3億 | -¥2億 | -¥4億 |
| 経常利益 | -¥3億 | -¥3億 | -¥2億 | -¥4億 |
| 当期純利益 | -¥3億 | -¥3億 | ¥1億 | -¥3億 |
| EPS | -¥26.42 | -¥20.32 | ¥8.92 | - |
| 営業利益率 | -332.06% | -129.96% | -134.77% | -520.59% |
| 貸借対照表 | ||||
| 総資産 | ¥23億 | ¥21億 | ¥19億 | ¥35億 |
| 純資産 | ¥19億 | ¥16億 | ¥17億 | ¥33億 |
| 総負債 | ¥4億 | ¥5億 | ¥2億 | ¥2億 |
| 現金 | ¥22億 | ¥20億 | ¥18億 | ¥34億 |
| 有利子負債 | ¥3億 | ¥4億 | ¥0億 | - |
| 自己資本比率 | 81.99% | 76.92% | 91.92% | 94.85% |
| D/Eレシオ | 0.17 | 0.22 | 0.00 | 0.00 |
| キャッシュフロー | ||||
| 営業CF | -¥3億 | -¥2億 | -¥2億 | -¥3億 |
| 投資CF | ¥0億 | -¥0億 | ¥4億 | - |
| 財務CF | ¥1億 | ¥0億 | -¥1億 | ¥19億 |
| フリーCF | -¥3億 | -¥2億 | -¥2億 | -¥3億 |
| 効率性 | ||||
| ROE | -18.00% | -16.08% | 6.59% | -9.07% |
| ROA | -14.76% | -12.37% | 6.06% | -8.60% |
最新IR情報
最新ニュース (5件)
テスホールディングス---子会社による大口受注 - ｄメニューニュース ↗
企業情報
会社概要
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, cutaneous angio-sarcoma, coronavirus lung injury, and interstitial lung disease associated with systemic scleroderma; RS5441, PAI-1 inhibitor for the treatment of alopecia disease that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder and menopausal disorder, which is in phase 1 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Sendai, Japan.
